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Longitudinal study of effects of
patient characteristics on direct
costs in Alzheimer disease
C.W. Zhu, PhD; N. Scarmeas, MD, MSc; R. Torgan, MPH; M. Albert, PhD; J. Brandt, PhD;
D. Blacker, MD, ScD; M. Sano, PhD; and Y. Stern, PhD
Abstract—Objectives: To estimate long-term trajectories of direct cost of caring for patients with Alzheimer disease (AD)
and examine the effects of patients’ characteristics on cost longitudinally. Methods: The sample is drawn from the
Predictors Study, a large, multicenter cohort of patients with probable AD, prospectively followed up annually for up to 7
years in three university-based AD centers in the United States. Random effects models estimated the effects of patients’
clinical and sociodemographic characteristics on direct cost of care. Direct cost included cost associated with medical and
nonmedical care. Clinical characteristics included cognitive status (measured by Mini-Mental State Examination), func-
tional capacity (measured by Blessed Dementia Rating Scale [BDRS]), psychotic symptoms, behavioral problems, depres-
sive symptoms, extrapyramidal signs, and comorbidities. The model also controlled for patients’ sex, age, and living
arrangements. Results: Total direct cost increased from approximately $9,239 per patient per year at baseline, when all
patients were at the early stages of the disease, to $19,925 by year 4. After controlling for other variables, a one-point
increase in the BDRS score increased total direct cost by 7.7%. One more comorbid condition increased total direct cost by
14.3%. Total direct cost was 20.8% lower for patients living at home compared with those living in an institutional setting.
Conclusions: Total direct cost of caring for patients with Alzheimer disease increased substantially over time. Much of the
cost increases were explained by patients’ clinical and demographic variables. Comorbidities and functional capacity were
associated with higher direct cost over time.
NEUROLOGY 2006;67:998–1005
Alzheimer disease (AD) is the third most costly dis-
ease to society in the United States.1 Average annual
costs of caring for patients with AD have been esti-
mated at $80 billion to $100 billion in the United
States.2 Several important factors that influence the
cost of AD have been identified in the literature,
including dementia disease severity,3-12 comorbid
medical conditions,7,13,14 behavioral problems,12,15,16
neuropsychiatric symptoms,17 or extrapyramidal
signs.18 However, much of the AD cost literature re-
mains cross-sectional and cannot examine cost tra-
jectories over time. The two studies that followed
patients over time either used data from two time
points over short periods of time or used a small
nonrepresentative sample; they are therefore limited
their ability to estimate long-term disease cost tra-
jectories.19,20 Consequently, we do not yet know how
cost changes as disease progresses nor the relation-
ship between cost and clinical factors over time.
Direct costs of AD related to medical and nonmed-
ical care are substantial. In an earlier work from the
Predictors Study, a large, multicenter study of pa-
tients with probable AD followed from early stages of
the disease, we examined cross-sectionally the asso-
ciation between patient characteristics and direct
costs.21 In this study, we aim to extend our previous
work and estimate empirically long-term trajectories
of direct cost of AD and relate them to patients’ clin-
ical and sociodemographic characteristics.
Methods. Sample. The sample used in this study is drawn
from the Predictors 2 cohort and consisted of 204 patients with
probable AD recruited from three sites: Columbia University Med-
ical Center, Johns Hopkins School of Medicine, and Massachu-
setts General Hospital. The study was approved by each local
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institutional review board. The inclusion and exclusion criteria
are fully described elsewhere.22-24 Briefly, subjects met DSM-III-R
criteria for primary degenerative dementia of the Alzheimer type
and National Institute of Neurological Disorders and Stroke–
Alzheimer’s Disease and Related Disorder Association criteria for
probable AD. Enrollment required a modified Mini-Mental State
Examination score of 30 or greater, equivalent to a score of ap-
proximately 16 or greater on the Folstein Mini-Mental State Ex-
amination (MMSE).25,26 Because subjects were followed up at
academic AD centers, they were well characterized with high de-
grees of certainty in their AD diagnosis.
Recruitment of patients in the Predictors Study began in 1998.
For the current analysis sample, baseline data were collected for
13.3% of patients in 1998, 8.3% in 1999, 24.3% in 2000, 26.0% in
2001, 15.5% in 2002, 11.1% in 2003, and 1.1% in 2004. After the
baseline interview, all patients were followed semiannually, with
annual assessments of resource utilization. At this point in the
study, patients have each had at least one assessment in resource
utilization, and 82.4% have had two or more assessments. Specif-
ically, 36 patients had one assessment only (at baseline), 62 had
two assessments (baseline and one follow-up visit), 51 had three
assessments (baseline and two follow-up visits), 36 had four as-
sessments, 11 had five assessments, and 2 had six assessments.
Median follow-up for the cohort was 2 years, and maximum
follow-up time was 7 years. Patients who did not respond at a
particular visit could respond at a subsequent visit. We excluded 6
patients with missing cost data from our analysis sample. Each of
these 6 patients was assessed once at baseline and would have
contributed 6 observations to the analysis sample. The final anal-
ysis sample consisted of 524 observations from 198 patients.
Measures. Data on several clinical characteristics that can be
assessed easily and reliably by a clinician were recorded at each
visit. At baseline and annually thereafter, data on patients’ utili-
zation of seven domains of medical and nonmedical care also were
collected. We converted physical quantities for each domain of
care into monetary values based on cost estimates from several
public sources.27-30 We summed costs across all domains to obtain a
total direct cost as a measure of intensity of resource utilization.
We briefly describe below the clinical characteristics, health ser-
vices utilization, and cost outcomes used in this study. Details of
our costing methods were reported in an earlier study.21
Clinical characteristics. Disease progression was character-
ized by transition from milder stages of dementia to more severe
stages, measured by MMSE.25 Higher MMSE scores indicate bet-
ter cognitive status. Blessed Dementia Rating Scale (BDRS) Parts
I (Instrumental Activities of Daily living, IADLs) and II (Basic
Activities of Daily living, BADLs) was used to assess patients’
functional capacity.31 This is a 17-point scale, with higher scores
indicating worse functional status. Columbia University Scale for
Psychopathology in Alzheimer’s Disease, a semistructured inter-
view administered by a physician or a trained research technician,
was used to measure the presence or absence of psychotic symp-
toms, behavior problems, and depressive symptoms.32 Following
previous work,33,34 we constructed a dichotomous variable to indi-
cate the presence of psychotic symptoms if the patient had any
delusions, hallucinations, or illusions. We constructed a dichoto-
mous variable to indicate the presence of behavioral problems if
the patient had any of the following five symptoms: wandering
away from home or caregiver, verbal outbursts, physical threats
or violence, agitation or restlessness, or sundowning (more confu-
sion at night or during the evening, compared with during the
day). We also constructed a dichotomous variable to indicate the
presence of depressive symptoms if the patient had any depressed
mood (i.e., sad, depressed, blue, down in the dumps) and either
had difficulty sleeping or had a change in appetite. A modified
Unified Parkinson’s Disease Rating Scale was used to measure
the presence or absence of extrapyramidal signs (EPS).35,36 Follow-
ing our previous work,24,37 we constructed a dichotomous indicator
for the presence of EPS if any of the following 11 items was rated
2 or higher (with 0 being normal and 4 indicating maximum
impairment): speech, facial expression, tremor at rest, neck rigid-
ity, right arm rigidity, left arm rigidity, right leg rigidity, left leg
rigidity, posture, gait, or bradykinesia. Patients’ medical histories
were used to construct a modified version of the Charlson index of
comorbidity.34,37,38 Comorbidities included items for myocardial in-
farction, congestive heart failure, peripheral vascular disease, hy-
pertension, chronic obstructive pulmonary disease, arthritis,
gastrointestinal diseases, liver disease, diabetes, chronic renal dis-
ease, and systemic malignancy from the baseline visit. No patients
with strokes, metastatic tumors, or AIDS were included in the
sample. Finally, disease duration was estimated by a neurologist
based on interviews with the patient and informant at the base-
line visit.
Sociodemographic characteristics. At the baseline visit, demo-
graphic characteristics (e.g., age, ethnicity, sex, education) were
recorded. Because patients’ living arrangement may change over
time and patterns of health service utilization and costs may
differ substantially between patients in different living arrange-
ments,39 information on patients’ living arrangements was col-
lected at each follow-up visit.
Outcomes. Patients and informants reported utilization of
seven domains of medical and nonmedical care. Medical care in-
cluded hospitalization, outpatient treatment and procedures, as-
sistive devices, and medications. Nonmedical care included home
health aides, respite care, and adult day care. We annualized
utilization rates when domains were reported for 3 months (outpa-
tient medical test, treatments, and procedures; nonmedical care)
and 6 months (medications). To convert physical quantities of
resource use into monetary values, we multiplied for each domain
the quantity used for that domain and the corresponding unit
cost, and then summed across all domains to obtain a total
direct cost as a measure of intensity of total resource utilization.
Unit costs for each domain were obtained from several databases
and described in detail in an earlier report.21,27-30 All cost values
were adjusted to constant 2004 dollars using the medical care
component of the Consumer Price Index.40
Analysis. Because total direct cost was highly skewed to the
right (skewness  2.26), we examined log cost as the dependent
variable. Three patients at five different visits reported zero cost,
generating missing values on log costs. Instead of arbitrarily add-
ing a constant (e.g., $1) to the cost measure before log-
transformation, we excluded these five observations. Because the
number of observations with zero cost was so small, excluding
them did not change the cost distribution in the sample. The
Shapiro–Wilk W test did not reject the hypothesis that log cost
was normally distributed (p  0.08).
In our multivariate analysis, we aimed to estimate two compo-
nents of change in total direct cost trajectories as disease
progresses over time: within-person change and between-person
change. We used random effects models (also known as hierarchi-
cal linear models, multilevel models, or random coefficient models)
to estimate these changes over time.41,42 The unit of observation
was person-year.
We hypothesized an overall upward trajectory of direct costs
for the sample as a whole. Time in this study was measured in
years after baseline (Time 0). We began by estimating a simple
model that included an intercept and time (year) as fixed effects,
and a random intercept term. In this model, the (fixed) intercept
estimates the average baseline cost. The coefficient on time (year)
estimates the average linear trend in direct costs over time. The
random intercept estimates deviations from average cost trajecto-
ries for each patient. We then included a term for time (year)
squared in the estimation model. The coefficient on the time-
squared term was statistically insignificant and was dropped in
subsequent models. In the next step, we included a random slope
in our estimation model to allow subjects to differ in their overall
rate of cost increase. Likelihood ratio tests suggested that cost
trajectories differed significantly across patients. Finally, we in-
cluded clinical and sociodemographic variables as fixed effects to
control for any systematic differences in our sample on these vari-
ables. The clinical variables included MMSE score, BDRS score,
number of comorbidities, and presence or absence of behavioral
problems, EPS, depressive and psychotic symptoms. Each of the
clinical variables was measured at each visit and was therefore
time variant.
Sociodemographic variables included age at baseline, sex, and
living arrangement at each visit. Patients’ living arrangement at
each visit was measured in the following four categories: at home,
in retirement homes, in assisted living facilities, or in nursing
homes. These four categories initially were entered separately in
the estimation model to examine the effects of different care envi-
ronments on costs. However, earlier estimation results suggested
that costs were not significantly different between patients who
lived in retirement homes, in assisted living facilities, or in nurs-
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ing homes, possibly because of the relatively small proportions of
patients in these groups in our sample. Therefore, these three
categories were combined in the final estimation model. Because
the patients in the sample were overwhelmingly white (96%), we
did not include race as an explanatory variable. In addition, we
controlled for site differences by including site dummy variables.
In this model, the fixed effects parameters are interpreted as the
average effect of each explanatory variable. The random effects
are interpreted as deviations from the average for each patient.
Our final model took the form
yit 1 2yearit 3wit 1t 2tyearit εit,
where yit is the log cost of patient i at year t, yearit is the corre-
sponding year, wit refers to the clinical and sociodemographic vari-
ables, 1t is the random intercept that allows baseline cost of each
patient to differ from average cost, 2t is the random slope that
allows the rate of change for each patient to differ from average
rate of change over time, εit is the random error, and the s are
the estimated fixed effects parameters.
Because our dependent variable was log-transformed, the coef-
ficient estimates are semielasticities. The interpretation of the
coefficient estimates requires some care. For continuous explana-
tory variables, a coefficient of ˆ estimates the proportional change
in direct cost for a unit change in the explanatory variable, hold-
ing all other variables constant. That is, for a unit increase in the
explanatory variable, direct cost increases by 100 ˆ percent. For
dichotomous explanatory variables, the corresponding propor-
tional change on cost of the explanatory variable from the refer-
ence group is estimated by
e
ˆ V ˆ
2  1 ,
holding all other variables constant.43 We interpreted these pro-
portional changes as the marginal effect of each explanatory vari-
able on direct cost. We used a Wald test to test the hypothesis that
all variables in the model were jointly significant. All analyses
were performed using Stata 9.0.44
Results. Sociodemographic and clinical characteristics.
Longitudinal patterns of demographic and clinical charac-
teristics of the sample are shown in table 1. The first row
in table 1 presents the number of patients who contributed
to our analysis sample at each visit. Differences in the
number of observations over the years of follow-up reflect
the continuous accrual of subjects even at present and
patient deaths (8%). During the period in which each sub-
ject was followed up, missed visits were rare: 15.6% miss-
ing one visit, 2.5% missed two visits, and 1% missed three
visits. Because only eight patients remained in years 5 and
6 (contributing to 12 observations), descriptive statistics of
the sample were presented for the first 4 years of the
study. The average patient in the sample was 76.3 years
old. Slightly more than half were women (55.9%). The pa-
tients in the sample were largely non-Hispanic white
(95.8%), well educated (with an average of 14.3 years of
schooling), and either married (59.9%) or widowed (31.1%).
At baseline, 85.9% of the patients lived at home, 8.1% lived
in a nursing home, and 6% lived in a retirement home or
an assisted living facility. There were no differences in
subjects’ sociodemographic characteristics across sites.
Because of the study inclusion criteria, all patients were
initially at the early stages of AD. At baseline, most pa-
tients (95%) were mildly demented, with a Clinical Demen-
tia Rating of 1;45 the mean MMSE score was 22.0 (SD 
3.7), and the mean BDRS score was 3.6 (SD  2.2). As
expected, patients’ cognition and function worsened over
time. Over time, MMSE and BDRS scores both worsened
monotonically. By the end of the study period or the last
assessment for patients who died, 71.2% of the cohort re-
mained mildly demented, 19.2% were moderately de-
mented, and 9.7% were severely demented. Neurologists’
estimate of duration of illness at baseline was 4.1 years
(SD  2.2 years). At baseline, half of the patients did not
have any comorbid conditions, 32% had one, 10% had two,
6% had three, and 2% had four comorbid conditions. On
average, patients had less than one comorbid condition
(mean  0.8). The most common comorbid conditions at
baseline included hypertension (36.1%), diabetes (9.7%),
and myocardial infarction (6.7%).
Utilization and annual per-patient costs over time.
Table 2 presents data on utilization rates, intensity of use,
and annual direct costs for medical and nonmedical care
over time. All patients used some type of medical care each
year, mainly because of high rates of medication use
(96% each year). There were no discernible trends over













Sample size* 198 132 93 59 30 524
Sociodemographic variables
Age at baseline, 76.4 76.7 76.8 75.5 74.6 76.3
mean (SD), y (8.1) (8.2) (8.5) (7.4) (8.2) (8.1)
Female, % 59.1 55.3 58.1 47.5 50.0 55.9
Race, %
White 94.9 97.0 94.6 96.6 96.7 95.8
Black 4.5 2.3 4.3 3.4 3.3 3.6
Other 0.5 0.8 1.1 0.0 0.0 0.6
Years of schooling, 14.3 14.6 14.3 14.5 13.6 14.3
mean (SD) (3.2) (3.1) (3.2) (3.2) (3.7) (3.2)
Marital status, %
Married 60.1 59.8 57.0 61.0 66.7 59.9
Widowed 30.8 31.1 31.2 33.9 26.7 31.1
Other 9.1 8.3 8.6 1.7 6.7 7.8
Living arrangement, %
At home 85.9 77.3 75.3 69.5 83.3 79.6
Nursing home 8.1 11.4 12.9 16.9 3.3 10.5
Retirement home 2.5 4.5 1.1 1.7 0.0 2.5
Assisted living facility 3.5 6.1 7.5 11.9 13.3 6.7
Site, %
Columbia 44.9 34.1 44.1 42.4 50.0 42.6
Johns Hopkins 23.2 24.2 19.4 20.3 36.7 23.5
Massachusetts General 31.8 41.7 36.6 37.3 13.3 34.0
Clinical characteristics
MMSE, mean (SD) 22.0 19.6 19.1 17.7 15.7 20.1
(3.7) (6.0) (6.2) (7.4) (7.8) (5.7)
BDRS total, mean (SD) 3.6 5.2 5.6 6.8 8.1 5.0
(2.2) (3.2) (3.4) (3.9) (3.5) (3.3)
Behavioral problems, % 42.4 49.2 60.2 57.6 60.0 50.6
EPS, % 14.1 20.5 18.3 23.7 16.7 17.7
Depressive symptoms, % 20.2 24.2 17.2 11.9 23.3 19.7
Psychotic symptoms, % 31.3 32.6 36.6 40.7 40.0 34.5
Modified comorbidity index 0.8 0.8 0.8 0.8 0.8 0.8
(0.9) (1.0) (1.0) (0.9) (0.9) (0.9)
* At baseline, data were collected from 198 patients. At year 1 and each
year thereafter through year 4, data were collected from 132, 93, 59, and
30 patients from the original 198 patients for a total number of 524
observations.
MMSE  Mini-Mental State Examination (range 0 to 30); BDRS 
Blessed Dementia Rating Scale (range 0 to 17); EPS  extrapyramidal
signs.
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time in the utilization rates of medications, outpatient
treatments or procedures, assistive devices, and hospital-
izations. Utilization rate of nonmedical care increased sub-
stantially from 15.7% at baseline to 40% at year 4. Average
number of medications taken increased from 6.4 at base-
line to 8.1 in year 4 (a 26.5% increase). Average intensity
of use did not change substantially for outpatient treat-
ments or procedures, assistive devices, and
hospitalizations.
In terms of average per-patient cost, cost of outpatient
treatments or procedures, assistive devices, and hospital-
izations fluctuated year to year, but medication cost in-
creased steadily from $2,872 to $4,301 (a 50% increase).
Total medical care costs and nonmedical care costs both
increased substantially, from $7,105 to $10,577 (a 49%
increase) and from $1,349 to $9,348 (a 7-fold increase).
Taken together, in this group of patients, total direct cost
per patient doubled from $9,239 at baseline to $19,925 at
year 4.
Adjusted medical costs over time. Table 3 presents
results of random effects regression models of log cost on
patients’ clinical and sociodemographic characteristics. We
began by specifying a simple model with only a random
intercept (results not shown). Results of the random inter-
cept model suggested that total direct cost increased by
16% each year, but cost differed substantially across pa-
tients. A second model that included both a random inter-
cept and a random slope suggested that total direct cost
increased by 13% each year, and there were substantial
differences in both baseline cost and rate of increase in
cost between patients. Our final model included both ran-
dom intercept and random slope terms and estimated the
effects on direct cost of patients’ clinical and sociodemo-
graphic characteristics. Results of this model (table 3) sug-
gested that patients’ clinical and sociodemographic
variables explained much of the time effect that was ob-
served. Specifically, higher BDRS scores and higher num-
ber of comorbid conditions were associated with higher
direct costs; women and patients living at home were asso-
ciated with lower direct costs. The coefficient estimate on
year in table 3 became insignificant, and that of total di-
rect cost increased only by 1.2% each year after controlling
for subjects’ clinical and sociodemographic variables.
Table 3 also presents marginal effects of each variable
on direct cost. For continuous explanatory variables, we
defined the marginal effect of an explanatory variable as
the proportional change in cost for a unit change in the
explanatory variable, holding all other variables constant.
For dichotomous explanatory variables, we defined the
marginal effect of an explanatory variable as the propor-
tional change in cost as the explanatory variable changes
from the reference group, holding all other variables con-
Table 2 Descriptive statistics of utilization and costs over time
Baseline Year 1 Year 2 Year 3 Year 4 All sample
Sample size 198 132 93 59 30 524
Utilization rate, %
Medical care
Medication 96.5 98.5 100.0 98.3 100.0 98.1
Outpatient treatment 72.7 66.7 75.3 71.2 70.0 71.4
Assistive device 42.9 31.8 37.6 40.7 50.0 38.9
Hospitalization 21.2 20.5 15.1 25.4 20.0 20.4
Nonmedical care 15.7 28.0 24.7 27.1 40.0 23.7
Intensity of use, mean (SD)
Medication 6.4 7.5 7.4 7.7 8.1 7.1
(3.5) (3.6) (3.1) (3.7) (3.8) (3.5)
Outpatient treatment 2.0 1.9 1.9 2.0 1.9 2.0
(2.1) (2.1) (2.2) (2.3) (2.4) (2.1)
Assistive device 0.8 0.6 0.6 0.8 1.3 0.7
(1.3) (1.2) (1.2) (1.3) (2.3) (1.3)
Hospitalization 0.3 0.2 0.2 0.4 0.4 0.3
(0.6) (0.5) (0.5) (0.7) (0.9) (0.6)
Per-patient cost, mean (SD)
Medication 2,872 3,349 3,874 4,186 4,301 3,403
(1,857) (2,014) (2,866) (2,604) (2,639) (2,294)
Outpatient treatment 1,786 1,397 1,458 1,374 1,589 1,559
(3,318) (3,351) (2,703) (2,183) (2,796) (3,046)
Assistive device 144 175 189 184 300 172
(337) (493) (648) (437) (448) (460)
Hospitalization 3,089 2,209 3,182 7,155 4,387 3,627
(8,081) (6,049) (11,639) (20,482) (16,407) (12,053)
Total medical care 7,105 7,890 8,699 12,899 10,577 8,753
(7,686) (9,060) (12,838) (20,301) (17,311) (12,875)
Total nonmedical care 1,349 5,000 4,672 2,429 9,348 3,835
(7,527) (16,339) (18,365) (5,709) (17,057) (14,121)
Total direct cost 9,239 12,105 13,371 15,328 19,925 12,587
(12,125) (19,514) (23,055) (20,968) (29,104) (20,849)
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stant. Results showed that after controlling for other vari-
ables, a one-point increase in the BDRS score increased
total direct cost by 7.7%, and one more comorbid condition
increased total direct cost by 14.3%. Log cost was 0.238
lower for women than for men, corresponding to a 21.5%
lowered total direct cost for women as compared with men.
Log cost was 0.225 lower for patients living at home than
those living in an institutional setting, corresponding to a
20.8% lowered direct cost for patients living at home.
Other clinical variables (MMSE scores, presence of behav-
ioral problems, EPS, depressive symptoms, and psychotic
symptoms) were not significantly associated with total di-
rect cost. Finally, results also showed substantial site dif-
ferences in costs, with the Boston site having lower cost
than Baltimore and New York City sites.
Discussion. In this study, we estimated empiri-
cally long-term trajectories of direct health care cost
for a sample of patients initially at early stages of
AD and related them to patients’ clinical and socio-
demographic characteristics. As discussed below, we
will investigate indirect costs in a separate report.
We estimated that total direct cost of caring for pa-
tients with AD was $9,239 per patient per year at
baseline, when all patients were in the early stages
of the disease. We also estimated that total direct
cost increased substantially at each subsequent
follow-up. By year 4, total direct cost more than dou-
bled to $19,925 per patient per year. The magnitude
of these cost estimates are consistent with existing
studies.21,46
With longitudinal data, we showed that much of
the cost increases were explained by patients’ clini-
cal and demographic variables. Without controlling
for other covariates, total direct cost increased by
approximately 13% each year. After controlling for
patients’ clinical and sociodemographic variables,
however, the time (year) effect became insignificant
and was only associated with a 1.2% increase in di-
rect cost each year.
The longitudinal analysis in this study confirms
results from an earlier cross-sectional study using
the same sample.21 There we found that small differ-
ences in function were associated with large differ-
ences in medical care costs; this study further
showed that the relationship between disease cost
and function was consistent over time. As a second-
ary analysis, we tested our models using BDRS fac-
tors instead of the total score to examine which
specific domains were most sensitive to cost in-
creases. As a group, the BDRS factors were signifi-
cantly associated with higher costs. Both IADLs and
BADLs factors were associated with higher direct
costs. Our longitudinal analysis also confirms the
relationship between comorbidities and higher costs.
A limitation of using the number of comorbidities is
that it treats each condition equally when some con-
ditions may be more costly than others. We tested
which comorbid conditions were associated with
higher cost by including each condition in our esti-
mation model instead of using the modified comor-
bidity index. Results show that myocardial
infarction, chronic obstructive pulmonary disease,
and chronic liver disease were significantly associ-
ated with higher direct cost. These results are con-
sistent with the findings in the Odense study; this
study reported that between baseline and 3-year
follow-up interviews in a sample of patients initially
living in the community, patients’ total health care
costs were significantly associated with disease pro-
gression (measured by transition to moderate or se-
vere dementia), development of and declines in
functional abilities, and transition in living arrange-
ment (moving from community to residential
homes).20
The effects of psychotic and behavior problems
and extrapyramidal signs on the cost of caring for
patients with AD are not yet well understood. Simi-
lar to our baseline study, but contrary to several
cross-sectional studies that examined the effects of
behavior problems12,15,16 and EPS18 on AD costs, we
did not find the presence of psychotic symptoms, be-
havior problems, or EPS to be significantly associ-
ated with increased direct cost of care. We believe
the nonsignificant results may be due to the rough-
ness of the measures used in this study. For exam-
ple, subcategories of extrapyramidal and psychotic
symptoms were grouped together, and we only used
dichotomous gradations of severity. Additionally, be-
havioral and psychiatric symptoms in AD fluctuate
Table 3 Random effects models of total direct costs
Dependent variable, log (cost)
Fixed effects parameters Coef SE
Marginal
effect
Year 0.012 0.038 1.171
MMSE score 0.001 0.009 0.082
BDRS score 0.077 0.020 7.705‡
Number of comorbidities 0.143 0.051 14.301‡
Behavior problems (1  present,
0  absent)
0.056 0.090 5.347
Extrapyramidal signs (1  present,
0  absent)
0.010 0.115 0.386
Depressive symptoms (1  present,
0  absent)
0.126 0.101 12.874
Psychotic symptoms (1  present,
0  absent)
0.102 0.096 10.198
Younger than 65 y
(1  yes, 0  no)
0.115 0.168 12.080
Women (1  yes, 0  no) 0.238 0.100 21.545†
Lives at home (1  yes, 0  no) 0.225 0.130 20.846*
Site (reference  Massachusetts
General)
Columbia 0.303 0.118 34.435†
Johns Hopkins 0.227 0.138 24.233*
* p  0.10.
† p  0.05.
‡ p  0.01.
Coef  coefficient; MMSE  Mini-Mental State Examination; BDRS 
Blessed Dementia Rating Scale.
1002 NEUROLOGY 67 September (2 of 2) 2006
 at COLUMBIA UNIVERSITY PERIODICAL on December 3, 2010www.neurology.orgDownloaded from 
over time, and particular symptoms can occur any
time during the course of AD.34 Persistence of these
symptoms also differs from symptom to symptom.47
Although our multivariate model with time-
dependent covariates takes into account the status of
patients’ symptoms (presence or absence) at each
visit, we will examine in detail the effects on costs of
finer gradations of subtype and severity of each
symptom in future studies.
Consistent with other studies,3,7 we found that
costs are substantially lower for patients living at
home than for those living in an institutional set-
ting. Possibly because the proportion of patients
who lived in retirement homes and assisted living
facilities were small, we were unable to separate
out the effects on cost of different institutional
living arrangements. The lower direct cost at home
as compared with that in institutional settings
suggests that interventions aimed at delaying or
preventing institutionalization could reduce direct
cost of care. However, potential cost savings in
direct cost of care with delayed institutionaliza-
tion need to be balanced with the potential in-
crease in cost to caregivers providing unpaid
care. In our future work, we will explore the rela-
tionship between the cost of caregiving and
institutionalization.
In this study, we also found that women had
21% lowered total direct cost compared with men.
This result is consistent with earlier studies that
found differences in health care utilization be-
tween men and women. For example, one study
found that in a sample of patients who eventually
developed AD, use of Medicare reimbursed pri-
mary care was lower in women than in men.48 An-
other study of a nationally representative sample
of noninstitutionalized disabled elderly reported
lower use of both paid home care and informal care
in women than in men, even within married house-
holds.49 Although the results of this study and
these earlier studies are consistent and suggest
gender disparities in health care utilization, this
result requires further investigation.
We found substantial cost differences across sites.
This result is consistent with regional differences in
health services utilization and costs documented in
the literature50 and, more specifically, a recent study
on service utilization and costs among patients with
AD.51 Because different sites were included in these
studies, results are not directly comparable across
studies. Further investigations are needed to exam-
ine whether variations in utilization and costs reflect
differences in regional preferences, availability or ac-
cess of services, ethnic and cultural differences, or
socioeconomic factors.
At this point in the study, 16 of the 198 patients
in the analysis sample have died, contributing to
42 observations in the longitudinal sample. Many
studies show substantially higher medical care uti-
lization and cost during the last year of life.52,53 To
examine the effects of including patients who died
in our analysis, we performed secondary analyses
in the following two ways. First, we reestimated
our model excluding the last observation of the
patients who died (i.e., 16 observations dropped).
We also reestimated our model excluding these pa-
tients entirely (i.e., 42 observations dropped). Re-
sults of these models were similar to those
reported in this study.
There are several limitations to our study. Pa-
tients were selected from tertiary care university
hospitals and specialized diagnostic and treatment
centers and thus represent a nonrandom sample of
those affected by AD in the population. The patients
in our sample also were predominantly white and
highly educated. Caution is needed in generalizing
the results of this study to patients of other ethnici-
ties, to patients with lower levels of education and
income, and to community AD patients. Future re-
search will need to examine AD cost trajectories in
samples that are more representative of the general
population.
It should be noted that the cost estimates reported
in this study are total direct cost associated with
caring for patients with AD and not incremental
costs due to AD. For example, costs of medications
include costs from all medications and not only those
from antidementia agents. To estimate the incre-
mental costs due to AD, a comparison longitudinal
sample of non-AD patients with otherwise similar
characteristics is needed. However, the construction
of a non-AD comparison group is beyond the scope of
this study. Many studies have documented the high
indirect cost of care for patients with AD and docu-
mented its association with a number of clinical vari-
ables.8,10,15,21,51,54,55 Most of these studies, like those
that examined direct cost of care, are cross-sectional.
In future studies, we will examine the trajectories of
indirect cost of caring for patients with AD and ex-
amine its relationship with important clinical
characteristics.
In this study, resource utilization was reported
by informants (mostly caregivers) and patients.
Self-reported data may be problematic in studies of
patients with AD because of the patients’ inability
to reliably report on service utilization and the
necessity of using proxies to obtain information.
We are not aware of any studies on the accuracy of
caregiver-reported resource utilization data. How-
ever, caregivers have been shown to accurately re-
port information on care recipients’ medical
conditions.56 Our results may be biased if there are
systematic differences between caregivers’ reports
on medical conditions and resource use. However
there is no reason to believe this is the case.
In general, confidence in our findings is
strengthened by several factors. A major contribu-
tion of the current analyses lies in the careful di-
agnosis and clinical follow-up that patients
received. Clinical diagnosis took place in univer-
sity hospitals with specific expertise in dementia
and was based on uniform application of widely
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accepted criteria via consensus diagnostic confer-
ence procedures. The clinical diagnosis of AD has
been confirmed in a high proportion (93%) of those
who have come to postmortem evaluation.24 The
patients were followed up prospectively, which
eliminates the potential biases inherent in deriv-
ing information from retrospective chart reviews.
Evaluations were performed annually, which pro-
vides multiple assessments of cost and therefore
permits more accurate coefficient estimates. Our
cohort had a high rate of follow-up participation,
with few missing data. Clinical signs of interest
were ascertained and coded in a standardized fash-
ion at each visit. Finally, patients were recruited
at early stages of the disease and followed for long
periods of time. Analysis is not compressed in
time, and the cohort describes the full range of
progression over time. Longer-term effects on costs
are therefore more easily interpreted.
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Sudden death after air travel in a patient
with colloid cyst
B.C. ter Meulen, MD, Department of Neurology;
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and Immunology, Erasmus Medical Centre, Rotterdam,
The Netherlands
A 19-year-old previously healthy woman presented with sud-
den headache and nausea after a transcontinental flight. She
rapidly became comatose. A CT scan showed a biventricular
hydrocephalus (figure). A ventricular drain was inserted to re-
lieve intracranial pressure, but her clinical condition failed to
improve. The patient died 24 hours after admission. The most
notable finding at autopsy was a colloid cyst obstructing the
foramen of Monro. Few similar cases have been reported.1,2 We
conclude that patients harboring colloid cysts are prone to baro-
trauma with fatal outcome.
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Figure. On admission, a CT scan showed a biventricular hydrocephalus (A). Autopsy showed a colloid cyst of the third
ventricle (arrow) (B).
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